A research team has investigated a new combination therapy against cancer. This therapy employs systemic administration of the tissue hormone interferon-I combined with local application of Imiquimod.
NEW YORK--(BUSINESS WIRE)--PESG Research releases new market update: Silexion Therapeutics (NASDAQ: SLXN)* continues to strengthen its position in the precision oncology landscape with breakthrough ...
CNS-directed AAV gene therapy shows milder immune responses compared to systemic administration, reducing peripheral immune activation and systemic toxicities. Direct CNS delivery can bypass ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results